With nothing more than a quick view of its chart and a passing glance at the headlines, it would be easy to decide Gilead Sciences, Inc. (NASDAQ:GILD) is best left avoided. The GILD stock price took a fairly big tumble after the release of …
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to …
Cologuard-maker Exact Sciences sees stock jump on revenue rise Exact Sciences stock jumped Tuesday after the company reported a 152% increase in revenue. Check out this story on jsonline.com: …
Orbital Sciences Corp’s stock keeps going up, but a technical snag has their latest space mission at a stand-still. The company’s recent stock market performance shows that Wall Street follows science and technology news… but not …
The surprising part is that Gilead's shares slumped last month despite the late-stage success of its next major HIV single-tablet drug regimen: a fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide indicated for the …
WASHINGTON — Vienna, Virginia-based biotechnology company Cel-Sci, currently running late-stage clinical trials with patients for its head and neck cancer treatment, watched its stock fall more than 30 percent in early Tuesday trading …
The stock of the Material Sciences Corporation skidded 16 percent yesterday after the company said fake bookkeeping entries had forced it to restate profits for the last three years. The company, a maker of coated materials based in Elk …
Leading antiviral treatments have made Gilead Sciences (NASDAQ: GILD) more profitable than any of its Big Pharma peers, but the stock is trading at bargain-bin prices. Sales of its lead product have fallen in recent quarters, and …
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …
Yahoo!2mon